EGRX - Eagle Pharmaceuticals, Inc.
| Previous Close | 51.72 |
| Open | 51.54 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 49.98 - 53.20 |
| 52 Week Range | 36.03 - 85.66 |
| Volume | 165,166 |
| Avg. Volume | 203,175 |
| Market Cap | 734.089M |
| Beta (3Y Monthly) | 2.31 |
| PE Ratio (TTM) | 25.22 |
| EPS (TTM) | 2.09 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 57.00 |
- Zacks•4 days ago
New Strong Sell Stocks for April 22nd
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- Business Wire•4 days ago
CMS Establishes Unique J-Code for BELRAPZO™ (Bendamustine 500mL Hydrochloride Injection)
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code, or J-code (J9036), for BELRAPZO™ (bendamustine 500mL hydrochloride injection). Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019.
- Business Wire•11 days ago
Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA™ with Teva Pharmaceuticals International GmbH
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced that it has expanded its existing BENDEKA™ (bendamustine hydrochloride) licensing agreement with Teva Pharmaceuticals International GmbH (“Teva”). Under the terms of the revised licensing agreement, beginning on October 1, 2019, Eagle’s royalty payment will increase from 25% to 30% of BENDEKA net U.S. sales, provided that BENDEKA’s orphan drug exclusivity has not been rescinded, withdrawn or waived by such date.
- Markit•17 days ago
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for EGRX with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding EGRX are favorable, with net inflows of $1.65 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•23 days ago
Don't Sell Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Before You Read This
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll s...
- GlobeNewswire•29 days ago
Consolidated Research: 2019 Summary Expectations for Penn National Gaming, Nomad Foods, Americold Realty Trust, Cboe Global Markets, Eagle Pharmaceuticals, and National Commerce — Fundamental Analysis, Key Performance Indications
NEW YORK, March 28, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT
Q4 2018 Eagle Pharmaceuticals Inc Earnings Call
Motley Fool•2 months agoEagle Pharmaceuticals Inc (EGRX) Q4 2018 Earnings Conference Call Transcript
EGRX earnings call for the period ending December 31, 2018.
- Business Wire•2 months ago
Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results
-- Q4 2018 net income was $0.88 per basic and $0.86 per diluted share and adjusted non-GAAP net income was $1.23 per basic and $1.20 per diluted share --
- ACCESSWIRE•2 months ago
Eagle Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 ...
- Simply Wall St.•2 months ago
Is Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) ROE Of 15% Impressive?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While some investors are already well versed in financial metricsRead More...
- Zacks•2 months ago
Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, February 28, 2019, before the market opens.
- Zacks•2 months ago
Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•2 months ago
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- Simply Wall St.•4 months ago
Does Eagle Pharmaceuticals, Inc.’s (NASDAQ:EGRX) CEO Pay Matter?
Scott Tarriff became the CEO of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) in 2007. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- Business Wire•4 months ago
Eagle Pharmaceuticals, Inc. to Present at 37th Annual J.P. Morgan Healthcare Conference
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 37th Annual J.P.
